NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist $500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhancec
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.



* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

***COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31***

***Dear valued STN customer,***

***In an effort to enhance your experience with STN, we would***
***like to better understand what you find useful. Please take***
***approximately 5 minutes to complete a web survey.***

***If you provide us with your name, login ID, and e-mail address, you***
***will be entered in a drawing to win a free iPod(R). Your responses***
***will be kept confidential and will help us make future improvements***
***to STN.***

***Take survey: http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW ***

***Thank you in advance for your participation.***

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:44:46 ON 18 MAY 2006

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 11:44:56 ON 18 MAY 2006


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

DICTIONARY FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> s lpy/SQSP
L1     159373 LPY/SQSP

=> s l1 and SQL=<10
      622645 SQL=<10
L2        656 L1 AND SQL=<10

=> file caplus
COST IN U.S. DOLLARS                    SINCE FILE     TOTAL
                                 ENTRY   SESSION
FULL ESTIMATED COST                        33.65     33.86
```

FILE 'CAPLUS' ENTERED AT 11:45:45 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.




FILE COVERS 1907 - 18 May 2006 VOL 144 ISS 21
FILE LAST UPDATED: 16 May 2006 (20060516/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l2
L3         521 L2

=> s cancer? or neoplas? or tumor?
      292904 CANCER?
      449273 NEOPLAS?
      427701 TUMOR?
L4     708462 CANCER? OR NEOPLAS? OR TUMOR?

=> s l3 and l4
```

```
L5        218 L3 AND L4

=> s l3 (l) l4
L6         91 L3 (L) L4

=> s l6 not py>2002
     3859922 PY>2002
L7         30 L6 NOT PY>2002

=> d ibib 1-8

L7  ANSWER 1 OF 30  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2004:200078  CAPLUS
DOCUMENT NUMBER:        140:229427
TITLE:                  Cancer immunotherapy and diagnosis using immunogenic
                        peptides from human cytochrome P 450 1B1
INVENTOR(S):            Schultze, Joachim L.; Vonderheide, Robert H.; Sherr,
                        David; Nadler, Lee M.; Maecker, Britta; Von
                        Bergwelt-Baildon, Michael
PATENT ASSIGNEE(S):     Dana-Farber Cancer Institute, Inc., USA; Trustees of
                        Boston University
SOURCE:                 PCT Int. Appl., 120 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

    PATENT NO.         KIND  DATE       APPLICATION NO.       DATE
    ---------------    ----  --------   -------------------   --------
    WO 2001035810      A2    20010525   WO 2000-US31513       20001115
    WO 2001035810      A3    20020110
       W:  CA, JP, US
       RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
           PT, SE, TR
    CA 2390882         AA    20010525   CA 2000-2390882       20001115
    EP 1241945         A2    20020925   EP 2000-980436        20001115
       R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, FI, CY, TR
PRIORITY APPLN. INFO.:                  US 1999-165590P    P  19991115
                                        WO 2000-US31513    W  20001115

L7  ANSWER 2 OF 30  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2002:486038  CAPLUS
DOCUMENT NUMBER:        138:66278
TITLE:                  Cell cycle phase perturbations and apoptosis in tumour
                        cells induced by aplidine
AUTHOR(S):              Erba, E.; Bassano, L.; Di Liberti, G.; Muradore, I.;
                        Chiorino, G.; Ubezio, P.; Vignati, S.; Codegoni, A.;
                        Desiderio, M. A.; Faircloth, G.; Jimeno, J.;
                        D'Incalci, M.
CORPORATE SOURCE:       Cancer Pharmacology Laboratory, Department of
                        Oncology, Instituto di Richerche Farmacologiche Mario
                        Negri, Milan, 20157, Italy
SOURCE:                 British Journal of Cancer (2002), 86(9), 1510-1517
                        CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER:              Nature Publishing Group
DOCUMENT TYPE:          Journal
LANGUAGE:               English
REFERENCE COUNT:        25    THERE ARE 25 CITED REFERENCES AVAILABLE
                        RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7  ANSWER 3 OF 30  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2002:469230  CAPLUS
DOCUMENT NUMBER:        138:32948
TITLE:                  DNA repair protein levels vis-a-vis anticancer drug
                        resistance in the human tumor cell lines of the
                        National Cancer Institute drug screening program
AUTHOR(S):              Xu, Zhiyuan; Chen, Zhong-Ping; Malapetsa, Areti;
                        Alaoui-Jamall, Moulay; Bergeron, Josee; Monks, Anne;
                        Myers, Timothy G.; Mohr, Gerard; Sausville, Edward A.;
                        Scudiero, Dominic A.; Aloyz, Raquel; Panasci, Lawrence
                        C.
CORPORATE SOURCE:       Lady Davis Institute for Medical Research, Sir
```

Mortimer B Davis-Jewish General Hospital, Montreal, QC, H3T 1E2, Can.
SOURCE: Anti-Cancer Drugs (2002), 13(5), 511-519
CODEN: ANTDEV; ISSN: 0959-4973
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:261896 CAPLUS
DOCUMENT NUMBER: 136:353907
TITLE: Phage display particles expressing tumor-specific antigens induce preventive and therapeutic anti-tumor immunity in murine P815 model
AUTHOR(S): Wu, Yuzhang; Wan, Ying; Bian, Jiang; Zhao, Jianping; Jia, ZhengCai; Zhou, Liyun; Zhou, Wei; Tan, Yang
CORPORATE SOURCE: The Institute of Immunology, The Third Medicine University, Chungking, 400038, Peop. Rep. China
SOURCE: International Journal of Cancer (2002), 98(5), 748-753
CODEN: IJCNAW; ISSN: 0020-7136
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:348043 CAPLUS
DOCUMENT NUMBER: 135:120918
TITLE: Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A
AUTHOR(S): Markiewicz, Mary A.; Fallarino, Francesca; Ashikari, Andrew; Gajewski, Thomas F.
CORPORATE SOURCE: Departments of Pathology, Committee on Immunology, University of Chicago, Chicago, IL, 60637, USA
SOURCE: International Immunology (2001), 13(5), 625-632
CODEN: INIMEN; ISSN: 0953-8178
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:678462 CAPLUS
DOCUMENT NUMBER: 133:348838
TITLE: The B subunit of shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens
AUTHOR(S): Haicheur, Nacilla; Bismuth, Emmanuelle; Bosset, Sophie; Adotevi, Olivier; Warnier, Guy; Lacabanne, Valerie; Regnault, Armelle; Desaymard, Catherine; Amigorena, Sebastian; Ricciardi-Castagnoli, Paola; Goud, Bruno; Fridman, Wolf H.; Johannes, Ludger; Tartour, Eric
CORPORATE SOURCE: Unite d'Immunologie Clinique, Institut de la Sante et de la Recherche Medicale, Unite 255, Universite Pierre et Marie Curie, Institut Curie, Paris, 75248, Fr.
SOURCE: Journal of Immunology (2000), 165(6), 3301-3308
CODEN: JOIMA3; ISSN: 0022-1767
PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:673031 CAPLUS
DOCUMENT NUMBER: 134:221118
TITLE: Immunogenicity of tumor peptides: Importance of

peptide length and stability of peptide/MHC class II complex
AUTHOR(S): Grohmann, Ursula; Belladonna, Maria Laura; Bianchi, Roberta; Orabona, Ciriana; Silla, Silvia; Squillacioti, Giuseppe; Fioretti, Maria Cristina; Puccetti, Paolo
CORPORATE SOURCE: Department of Experimental Medicine, Pharmacology Section, University of Perugia, Giochetto, I-06126, Italy
SOURCE: Cancer Immunology Immunotherapy (1999), 48(4), 195-203
CODEN: CIIMDN; ISSN: 0340-7004
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:227537 CAPLUS
DOCUMENT NUMBER: 132:262172
TITLE: Use of neoangiogenesis markers for diagnosis and treatment of tumors
INVENTOR(S): Krause, Werner; Muschick, Peter
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000018439 | A2 | 20000406 | WO 1999-EP7198 | 19990929 |
| WO 2000018439 | A3 | 20000914 | | |
| W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, ES, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| DE 19845798 | A1 | 20000413 | DE 1998-19845798 | 19980929 |

PRIORITY APPLN. INFO.: DE 1998-19845798 A 19980929

=> d kwic 7

L7 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
IT ***145882-36-6*** 329687-10-7 329687-11-8 329687-12-9 329687-13-0
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(immunogenicity of ***tumor*** peptides and the importance of peptide length and stability of peptide/MHC class II complex)

=> d kwic 6

L7 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2006 ACS on STN
IT 138831-86-4DP, fusion protein with Shiga toxin B subunit
***145882-36-6DP*** , fusion protein with Shiga toxin B subunit
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(B subunit of Shiga toxin fused to a ***tumor*** antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens)

=> d his

(FILE 'HOME' ENTERED AT 11:44:46 ON 18 MAY 2006)

```
   FILE 'REGISTRY' ENTERED AT 11:44:56 ON 18 MAY 2006
L1      159373 S LPY/SQSP
L2         656 S L1 AND SQL=<10

   FILE 'CAPLUS' ENTERED AT 11:45:45 ON 18 MAY 2006
L3         521 S L2
L4      708462 S CANCER? OR NEOPLAS? OR TUMOR?
L5         218 S L3 AND L4
L6          91 S L3 (L) L4
L7          30 S L6 NOT PY>2002

=> s deliver? or target?
      281372 DELIVER?
      471201 TARGET?
L8     724854 DELIVER? OR TARGET?

=> s l8 and l7
L9          7 L8 AND L7

=> d ibib 1-7

L9  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2004:200078  CAPLUS
DOCUMENT NUMBER:        140:229427
TITLE:                  Cancer immunotherapy and diagnosis using immunogenic
                        peptides from human cytochrome P 450 1B1
INVENTOR(S):            Schultze, Joachim L.; Vonderheide, Robert H.; Sherr,
                        David; Nadler, Lee M.; Maecker, Britta; Von
                        Bergwelt-Baildon, Michael
PATENT ASSIGNEE(S):     Dana-Farber Cancer Institute, Inc., USA; Trustees of
                        Boston University
SOURCE:                 PCT Int. Appl., 120 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

    PATENT NO.         KIND  DATE       APPLICATION NO.       DATE
    ---------------    ----  --------   -------------------   --------
    WO 2001035810      A2    20010525   WO 2000-US31513       20001115
    WO 2001035810      A3    20020110
       W:  CA, JP, US
       RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
           PT, SE, TR
    CA 2390882         AA    20010525   CA 2000-2390882       20001115
    EP 1241945         A2    20020925   EP 2000-980436        20001115
       R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, FI, CY, TR
PRIORITY APPLN. INFO.:                  US 1999-165590P    P  19991115
                                        WO 2000-US31513    W  20001115

L9  ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2000:678462  CAPLUS
DOCUMENT NUMBER:        133:348838
TITLE:                  The B subunit of shiga toxin fused to a tumor antigen
                        elicits CTL and  ***targets***  dendritic cells to
                        allow MHC class I-restricted presentation of peptides
                        derived from exogenous antigens
AUTHOR(S):              Haicheur, Nacilla; Bismuth, Emmanuelle; Bosset,
                        Sophie; Adotevi, Olivier; Warnier, Guy; Lacabanne,
                        Valerie; Regnault, Armelle; Desaymard, Catherine;
                        Amigorena, Sebastian; Ricciardi-Castagnoli, Paola;
                        Goud, Bruno; Fridman, Wolf H.; Johannes, Ludger;
                        Tartour, Eric
CORPORATE SOURCE:       Unite d'Immunologie Clinique, Institut de la Sante et
                        de la Recherche Medicale, Unite 255, Universite Pierre
                        et Marie Curie, Institut Curie, Paris, 75248, Fr.
SOURCE:                 Journal of Immunology (2000), 165(6), 3301-3308
                        CODEN: JOIMA3; ISSN: 0022-1767
PUBLISHER:              American Association of Immunologists
DOCUMENT TYPE:          Journal
LANGUAGE:               English
REFERENCE COUNT:        63   THERE ARE 63 CITED REFERENCES AVAILABLE
```

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:549173 CAPLUS
DOCUMENT NUMBER: 131:175084
TITLE: Pharmaceutical formulation of a didemnin compound
INVENTOR(S): Beijnen, Jacob Hendrik; Nuyen, Bastiaan; Henrar, Roland Elizabeth Cornelis; Gomez, Andres; Jimeno, Jose
PATENT ASSIGNEE(S): Pharma Mar, S.A., Spain; Ruffles, Graham Keith
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9942125 | A1 | 19990826 | WO 1999-GB511 | 19990218 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2321116 | AA | 19990826 | CA 1999-2321116 | 19990218 |
| AU 9925389 | A1 | 19990906 | AU 1999-25389 | 19990218 |
| AU 754073 | B2 | 20021107 | | |
| BR 9908088 | A | 20001031 | BR 1999-8088 | 19990218 |
| EP 1054686 | A1 | 20001129 | EP 1999-905091 | 19990218 |
| EP 1054686 | B1 | 20020515 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2002503704 | T2 | 20020205 | JP 2000-532139 | 19990218 |
| AT 217532 | E | 20020615 | AT 1999-905091 | 19990218 |
| PT 1054686 | T | 20020930 | PT 1999-905091 | 19990218 |
| ES 2175940 | T3 | 20021116 | ES 1999-905091 | 19990218 |
| HK 1032538 | A1 | 20021206 | HK 2001-103194 | 20010507 |

PRIORITY APPLN. INFO.: GB 1998-3448 A 19980218
WO 1999-GB511 W 19990218
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE F(
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:123663 CAPLUS
DOCUMENT NUMBER: 130:310353
TITLE: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
AUTHOR(S): Toda, Masahiro; Rabkin, Samuel D.; Kojima, Hidefumi; Martuza, Robert L.
CORPORATE SOURCE: Georgetown Brain Tumor Center and Department of Neurosurgery, Georgetown University Medical Center, Washington, DC, 20007, USA
SOURCE: Human Gene Therapy (1999), 10(3), 385-393
CODEN: HGTHE3; ISSN: 1043-0342
PUBLISHER: Mary Ann Liebert, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:13451 CAPLUS
DOCUMENT NUMBER: 130:236141
TITLE: Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
AUTHOR(S): Fallarino, Francesca; Uyttenhove, Catherine; Boon, Thierry; Gajewskii, Thomas F.
CORPORATE SOURCE: Department of Pathology, University of Chicago,

Chicago, IL, USA
SOURCE: International Journal of Cancer (1999), 80(2), 324-333
CODEN: IJCNAW; ISSN: 0020-7136
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:531867 CAPLUS
DOCUMENT NUMBER: 123:74098
TITLE: Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen
AUTHOR(S): Alvarez, Manuel; Paull, Ken; Monks, Anne; Hose, Curtis; Lee, Jong-Seok; Weinstein, John; Grever, Mike; Bates, Susan; Fojo, Tito
CORPORATE SOURCE: Lab. Mol. Pharmacol., Developmtl. Therapeutics Program, National Cancer Institute, National Institutes Health, Bethesda, MD, 20892, USA
SOURCE: Journal of Clinical Investigation (1995), 95(5), 2205-14
CODEN: JCINAO; ISSN: 0021-9738
PUBLISHER: Rockefeller University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:519394 CAPLUS
DOCUMENT NUMBER: 122:263156
TITLE: Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL
AUTHOR(S): Irvine, Kari R.; McCabe, Barbra Jill; Rosenberg, Steven A.; Restifo, Nicholas P.
CORPORATE SOURCE: Surgery Branch, Natl. Inst. Health, Bethesda, MD, 20892, USA
SOURCE: Journal of Immunology (1995), 154(9), 4651-7
CODEN: JOIMA3; ISSN: 0022-1767
PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d ibib kwic 1-7

L9 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:200078 CAPLUS
DOCUMENT NUMBER: 140:229427
TITLE: Cancer immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1
INVENTOR(S): Schultze, Joachim L.; Vonderheide, Robert H.; Sherr, David; Nadler, Lee M.; Maecker, Britta; Von Bergwelt-Baildon, Michael
PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., USA; Trustees of Boston University
SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001035810 | A2 | 20010525 | WO 2000-US31513 | 20001115 |
| WO 2001035810 | A3 | 20020110 | | |
| W: CA, JP, US | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | | |
| CA 2390882 | AA | 20010525 | CA 2000-2390882 | 20001115 |
| EP 1241945 | A2 | 20020925 | EP 2000-980436 | 20001115 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

IE, FI, CY, TR
PRIORITY APPLN. INFO.: US 1999-165590P P 19991115
WO 2000-US31513 W 20001115

AB This invention is based on the discovery that cytochrome P 450 1B1 (CYP1B1) includes peptides that bind to HLA mols. Antigen-presenting cells that present such peptides on their surfaces, in complexes with HLA, can activate cytotoxic T lymphocytes (CTLs) to specifically lyse cells expressing CYP1B1, in an MHC-restricted fashion. Based on observations that CYP1B1 is a mediator of dioxin-related effects on tumorigenesis, CYP1B1 is identified as a potential universal tumor antigen; it is over-expressed in nearly 100% of human tumors, whereas the expression in normal tissue is low. Thus, the invention provides methods for the immunotherapeutic ***targeting*** of CYP1B1-expressing cells, such as cancer cells, and methods of monitoring the efficacy of such therapeutic methods. The invention provides methods for conducting cancer immunotherapy and diagnosis using cytochrome P 450 1B1 and peptide fragments thereof, as well as cotreatment with a second or third tumor-assocd. antigen (e.g., telomerase).

IT 330596-22-0, Cytochrome P 450 1B1 344835-77-4 433304-00-8
622837-65-4 622837-66-5 663892-54-4 663892-55-5 663892-56-6
663892-57-7 ***663892-58-8*** 663892-59-9 663892-60-2
663892-61-3 663892-62-4 663892-63-5 663892-64-6 663892-65-7
663892-66-8 663892-67-9 663892-68-0 663892-69-1 663892-70-4
663892-71-5 663892-72-6 663892-73-7 663892-74-8 663892-75-9
663892-76-0 663892-77-1 663892-78-2 663892-79-3 663892-80-6
663892-81-7 663892-82-8 663892-83-9 663892-84-0 663892-85-1
663892-86-2 663892-87-3 663892-88-4 663892-89-5 663892-90-8
663892-91-9 663892-92-0 663892-93-1 663892-94-2 663892-95-3
663892-96-4 ***663892-97-5*** 663892-98-6 663892-99-7
663893-00-3 663893-01-4 663893-02-5 663893-03-6 663893-04-7
663893-05-8 663893-06-9 663893-07-0 663893-08-1 663893-09-2
663893-10-5 663893-11-6 663893-12-7 663893-13-8 663893-14-9
663893-15-0 663893-16-1 663893-17-2 663893-18-3 663893-19-4
663893-20-7 663893-21-8 663893-22-9 663893-23-0 663893-24-1
663893-25-2 663893-26-3 663893-27-4 663893-28-5 663893-29-6
663893-30-9 663893-31-0 663893-32-1 663893-33-2 663893-34-3
663893-35-4 663893-36-5 663893-37-6 663893-38-7 663893-39-8
663893-40-1 663893-41-2 663893-42-3 663893-43-4 663893-44-5
663893-45-6 663893-46-7 663893-47-8 663893-48-9 663893-49-0
663893-50-3 663893-51-4 663893-52-5 663893-53-6 663893-54-7
663893-55-8 663893-56-9 663893-57-0 663893-58-1 663893-59-2
663893-60-5 663893-61-6 663893-62-7 663893-63-8 663893-64-9
663893-65-0 663893-66-1 663893-67-2 663893-68-3 663893-69-4
663893-70-7 663893-71-8 663893-72-9 663893-73-0 663893-74-1
663893-75-2 663893-76-3 663893-77-4 663893-78-5 663893-79-6
663893-80-9 663893-81-0 663893-82-1 663893-83-2 663893-84-3
663893-85-4 663893-86-5 663893-87-6 663893-88-7 663893-89-8
663893-90-1 663893-91-2 663893-92-3 663893-93-4 663893-94-5
663893-95-6 663893-96-7 663893-97-8 663893-98-9 663893-99-0
663894-00-6 663894-01-7 663894-02-8 663894-03-9 663894-04-0
663894-05-1 663894-06-2 663894-07-3 663894-08-4 663894-09-5
663894-10-8 663894-11-9 663894-12-0 663894-13-1 663894-14-2
663894-15-3 663894-16-4 663894-17-5 663894-18-6 663894-19-7
663894-20-0 663894-21-1 663894-22-2 663894-23-3 663894-24-4
663894-25-5 663894-26-6 663894-27-7 663894-28-8 663894-29-9
663894-30-2 663894-31-3 663894-32-4 663894-33-5 663894-34-6
***663894-35-7*** 663894-36-8 663894-37-9 663894-38-0
663894-39-1 663894-40-4 663894-41-5 663894-42-6 663894-43-7
663894-44-8 663894-45-9 663894-46-0 663894-47-1 663894-48-2
663894-49-3 663894-50-6 663894-51-7 663894-52-8 663894-53-9
663894-54-0 663894-55-1 663894-56-2 663894-57-3 663894-58-4
663894-59-5 663894-60-8 663894-61-9 663894-62-0 663894-63-1
663894-64-2 663894-65-3 663894-66-4 663894-67-5 663894-68-6
663894-69-7 663894-70-0 663894-71-1 663894-72-2 663894-73-3
663894-74-4 663894-75-5 663894-76-6 663894-77-7 663894-78-8
663894-79-9 663894-80-2 663894-81-3 663894-82-4
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
( ***cancer*** immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

IT 663894-83-5 663894-84-6 663894-85-7 663894-86-8 663894-87-9
663894-88-0 663894-89-1 663894-90-4 663894-91-5 663894-92-6
663894-93-7 663894-94-8 663894-95-9 663894-96-0 663894-97-1
663894-98-2 663894-99-3 663895-00-9 663895-01-0 663895-02-1

663895-03-2 663895-04-3 663895-05-4 663895-06-5 663895-07-6
663895-08-7 663895-09-8 663895-10-1 663895-11-2 663895-12-3
663895-13-4 663895-14-5 663895-15-6 663895-16-7 663895-17-8
663895-18-9 663895-19-0 663895-20-3 663895-21-4 663895-22-5
663895-23-6 663895-24-7 663895-25-8 663895-26-9 ***663895-27-0***
***663895-28-1*** 663895-29-2 663895-30-5 663895-31-6
663895-32-7 663895-33-8 663895-34-9 663895-35-0 663895-36-1
663895-37-2 663895-38-3 663895-39-4 663895-40-7 663895-41-8
663895-42-9 663895-43-0 663895-44-1 663895-45-2 663895-46-3
663895-47-4 663895-48-5 663895-49-6 663895-50-9 663895-51-0
663895-52-1 663895-53-2 663895-54-3 663895-55-4 663895-56-5
663895-57-6 663895-58-7 663895-59-8 663895-60-1 663895-61-2
663895-62-3 663895-63-4 663895-64-5 663895-65-6 663895-66-7
663895-67-8 663895-68-9 663895-69-0 663895-70-3 663895-71-4
663895-72-5 663895-73-6 663895-74-7 663895-75-8 663895-76-9
663895-77-0 663895-78-1 663895-79-2 663895-80-5 663895-81-6
663895-82-7 663895-83-8 663895-84-9 663895-85-0 663895-86-1
663895-87-2 663895-88-3 663895-89-4 663895-90-7 663895-91-8
663895-92-9 663895-93-0 663895-94-1 663895-95-2 663895-96-3
663895-97-4 663895-98-5 663895-99-6 663896-00-2 663896-01-3
663896-02-4 663896-03-5 663896-04-6 663896-05-7 663896-06-8
663896-07-9 663896-08-0 663896-09-1 663896-10-4 663896-11-5
663896-12-6 663896-13-7 663896-14-8 663896-15-9 663896-16-0
663896-17-1 663896-18-2 663896-19-3 663896-20-6 663896-21-7
663896-22-8 663896-23-9 663896-24-0 663896-25-1 663896-26-2
663896-27-3 663896-28-4 663896-29-5 663896-30-8 663896-32-0
663896-34-2 663896-35-3 663896-36-4 663896-37-5 ***663896-38-6***
663896-39-7 663896-40-0 663896-41-1 663896-42-2 663896-43-3
663896-44-4 663896-45-5 663896-46-6 663896-47-7 663896-48-8
663896-49-9 663896-50-2 663896-51-3 663896-52-4 663896-53-5
663896-54-6 663896-55-7 663896-56-8 663896-57-9 663896-58-0
663896-59-1 663896-60-4 663896-61-5 663896-62-6 663896-63-7
663896-64-8 663896-65-9 663896-66-0 663896-67-1 663896-68-2
663896-69-3 663896-70-6 663896-71-7 663896-72-8 663896-73-9
663896-74-0 663896-75-1 663896-76-2 663896-77-3 663896-78-4
663896-79-5 663896-80-8 663896-81-9 663896-82-0 663896-83-1
663896-84-2 663896-85-3 663896-86-4 663896-87-5 663896-88-6
663896-89-7 663896-90-0 663896-91-1 663896-92-2 663896-93-3
663896-94-4 663896-95-5 663896-96-6 663896-97-7 663896-98-8
663896-99-9 663897-00-5 663897-01-6 663897-02-7 663897-03-8
663897-04-9 663897-05-0 663897-06-1 663897-07-2 663897-08-3
663897-09-4 663897-10-7 663897-11-8 663897-12-9 663897-13-0
663897-14-1 663897-15-2 663897-16-3 663897-17-4 663897-18-5
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
( ***cancer*** immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)
IT 663897-19-6 663897-20-9 ***663897-21-0*** 663897-22-1
663897-23-2 663897-24-3 663897-25-4 663897-26-5 663897-27-6
663897-28-7 663897-29-8 663897-30-1 663897-31-2 663897-32-3
663897-33-4 663897-34-5 663897-35-6 663897-36-7 663897-37-8
663897-38-9 663897-39-0 663897-40-3 663897-41-4 663897-42-5
663897-43-6 663897-44-7 663897-45-8 663897-46-9 663897-47-0
663897-48-1 663897-49-2 663897-50-5 663897-51-6 663897-52-7
663897-53-8 663897-54-9 663897-55-0 663897-56-1 663897-57-2
663897-58-3 663897-59-4 663897-60-7 663897-61-8 663897-62-9
663897-63-0 663897-64-1 663897-65-2 663897-66-3 663897-67-4
663897-68-5 663897-69-6 663897-71-0 663897-72-1 663897-73-2
663897-74-3 663897-75-4 663897-76-5 663897-77-6 663897-78-7
663897-79-8 663897-80-1 663897-81-2 663897-82-3 663897-83-4
663897-84-5 663897-85-6 663897-86-7 663897-87-8 663897-88-9
663897-89-0 663897-90-3 663897-91-4 663897-92-5 663897-93-6
663897-94-7 663897-95-8 663897-96-9 663897-97-0 663897-98-1
663897-99-2 663898-00-8 663898-01-9 663898-02-0 663898-03-1
663898-04-2 663898-05-3 663898-06-4 663898-07-5 663898-08-6
663898-09-7 663898-10-0 663898-11-1 663898-12-2 663898-13-3
663898-14-4 663898-15-5 663898-16-6 663898-17-7 663898-18-8
663898-19-9 663898-20-2 663898-21-3 663898-22-4 663898-23-5
663898-24-6 663898-26-8 ***663898-27-9*** 663898-28-0
663898-29-1 663898-30-4 663898-31-5 663898-32-6 663898-33-7
663898-34-8 663898-35-9 663898-36-0 663898-37-1 663898-38-2
663898-39-3 663898-40-6 663898-41-7 663898-42-8 663898-43-9
663898-44-0 663898-45-1 663898-46-2 663898-47-3 663898-48-4
663898-49-5 ***663898-50-8*** 663898-51-9 663898-52-0

663898-53-1 663898-54-2 663898-55-3 663898-56-4 663898-57-5
663898-58-6 663898-59-7 663898-60-0 663898-61-1 663898-62-2
663898-63-3 663898-64-4 663898-65-5 663898-66-6 663898-67-7
663898-68-8 663898-69-9 ***663898-70-2*** 663898-71-3
663898-72-4 663898-73-5 663898-74-6 663898-75-7 663898-76-8
663898-77-9 663898-78-0 663898-79-1 663898-80-4 663898-81-5
663898-82-6 663898-83-7 663898-84-8 663898-85-9 663898-86-0
663898-87-1 663898-88-2 663898-89-3 663898-90-6 663898-91-7
663898-92-8 663898-93-9 663898-94-0 663898-95-1 663898-96-2
663898-97-3 663898-98-4 663899-00-1 663899-01-2 663899-02-3
663899-03-4 663899-04-5 663899-05-6 663899-06-7 663899-07-8
663899-08-9 663899-09-0 663899-10-3 663899-11-4 663899-12-5
663899-13-6 663899-14-7 663899-15-8 663899-16-9 663899-17-0
663899-18-1 663899-19-2 663899-20-5 663899-21-6 663899-22-7
663899-23-8 663899-24-9 663899-25-0 663899-26-1 663899-27-2
663899-28-3 663899-29-4 663899-30-7 663899-31-8 663899-32-9
663899-34-1 663899-36-3 663899-39-6 663899-41-0 663899-43-2
663899-45-4 663899-47-6 663899-49-8 663899-50-1 663899-51-2
663899-52-3 663899-53-4 663899-54-5 663899-55-6 663899-56-7
663899-57-8 663899-59-0 663899-61-4 663899-63-6 663899-65-8
663899-67-0 663899-69-2 663899-71-6
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
( ***cancer*** immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

IT 663899-73-8 663899-75-0 663899-77-2 663899-79-4 663899-81-8
663899-83-0 663899-85-2 663899-87-4 663899-88-5 663899-89-6
663899-90-9 663899-91-0 663899-92-1 663899-93-2 663899-94-3
663899-95-4 663899-96-5 663899-97-6 663899-98-7 663899-99-8
663900-00-3 663900-01-4 663900-02-5 ***663900-03-6***
663900-04-7 663900-05-8 663900-06-9 663900-07-0 663900-08-1
663900-09-2 663900-10-5 663900-11-6 663900-12-7 663900-13-8
663900-14-9 663900-15-0 663900-16-1 663900-17-2 663900-18-3
663900-19-4 663900-20-7 663900-21-8 663900-22-9 663900-23-0
663900-24-1 663900-25-2 663900-26-3 663900-27-4 663900-28-5
663900-29-6 663900-30-9 ***663900-31-0*** 663900-32-1
663900-33-2 663900-34-3 663900-35-4 663900-36-5 663900-37-6
663900-38-7 663900-39-8 663900-40-1 663900-41-2 663900-42-3
663900-43-4 663900-45-6 663900-46-7 663900-47-8 663900-49-0
663900-51-4 663900-52-5 663900-54-7 663900-55-8 663900-56-9
663900-57-0 663900-58-1 663900-59-2 663900-60-5 663900-61-6
663900-62-7 663900-63-8 663900-64-9 663900-65-0 663900-66-1
663900-67-2 663900-68-3 663900-69-4 663900-70-7 663900-71-8
663900-72-9 663900-73-0 663900-74-1 663900-75-2 663900-76-3
663900-77-4 663900-78-5 663900-79-6 663900-80-9 663900-81-0
663900-82-1 663900-83-2 663900-84-3 663900-85-4 663900-86-5
663900-87-6 663900-88-7 663900-89-8 663900-90-1 663900-91-2
663900-92-3 663900-93-4 663900-94-5 ***663900-95-6***
663900-96-7 663900-97-8 663900-98-9 663900-99-0 663901-00-6
663901-01-7 663901-02-8 663901-03-9 663901-04-0 663901-05-1
663901-06-2 663901-07-3 663901-08-4 663901-09-5 663901-10-8
663901-11-9 663901-12-0 663901-13-1 663901-14-2 663901-15-3
663901-16-4 663901-17-5 663901-18-6 663901-19-7 663901-20-0
663901-21-1 663901-22-2 663901-23-3 663901-24-4 663901-25-5
663901-26-6 663901-27-7 663901-28-8 663901-29-9 663901-30-2
663901-31-3 663901-32-4 663901-33-5 663901-34-6 663901-35-7
663901-36-8 663901-37-9 663901-38-0 663901-39-1 663901-40-4
663901-41-5 663901-42-6 663901-43-7 663901-44-8 663901-45-9
663901-46-0 663901-48-2 663901-50-6 663901-51-7 663901-52-8
663901-53-9 663901-54-0 663901-55-1 663901-56-2 663901-57-3
663901-58-4 663901-59-5 663901-60-8 ***663901-61-9***
663901-62-0 663901-63-1 663901-64-2 663901-65-3 663901-66-4
663901-67-5 663901-68-6 663901-69-7 663901-70-0 663901-71-1
663901-72-2 663901-73-3 663901-74-4 663901-75-5 663901-76-6
663901-77-7 663901-78-8 663901-79-9 663901-80-2 663901-81-3
663901-82-4 663901-83-5 663901-84-6 663901-85-7 663901-86-8
663901-87-9 663901-88-0 663901-89-1 663901-90-4 ***663901-91-5***
663901-92-6 663901-93-7 663901-94-8 663901-95-9 663901-96-0
663901-97-1 663901-98-2 663901-99-3 663902-00-9 663902-01-0
663902-02-1 663902-03-2 663902-04-3 663902-05-4 663902-06-5
663902-07-6 663902-08-7 663902-09-8 663902-10-1 663902-11-2
663902-12-3 663902-13-4 663902-14-5 663902-15-6 663902-16-7
663902-17-8 663902-18-9 663902-19-0
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP

(Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
( ***cancer*** immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

IT 663902-20-3 663902-21-4 663902-22-5 663902-23-6 663902-24-7
663902-25-8 663902-26-9 663902-27-0 663902-28-1 663902-29-2
663902-30-5 663902-31-6 663902-32-7 663902-33-8 663902-34-9
663902-35-0 663902-36-1 663902-37-2 663902-38-3 663902-39-4
663902-40-7 663902-41-8 663902-42-9 663902-43-0 663902-44-1
663902-45-2 663902-46-3 663902-47-4 663902-48-5 663902-49-6
663902-50-9 663902-51-0 663902-52-1 663902-53-2 663902-54-3
663902-55-4 663902-57-6 663902-59-8 663902-61-2 663902-63-4
663902-64-5 663902-65-6 663902-66-7 663902-67-8 663902-68-9
663902-69-0 663902-70-3 663902-71-4 663902-72-5 663902-73-6
663902-74-7 663902-75-8 663902-76-9 663902-77-0 663902-78-1
663902-79-2 663902-80-5 663902-81-6 663902-82-7 663902-83-8
663902-84-9 663902-85-0 663902-86-1 663902-87-2 663902-88-3
663902-89-4 663902-90-7 663902-91-8 663902-92-9 663902-93-0
663902-94-1 663902-95-2 663902-96-3 663902-97-4 663902-98-5
663902-99-6 663903-00-2 663903-01-3 663903-02-4 663903-03-5
663903-04-6 663903-05-7 663903-06-8 663903-07-9 663903-08-0
663903-09-1 663903-10-4 663903-11-5 663903-12-6 663903-13-7
663903-14-8 663903-15-9 663903-16-0 663903-17-1 663903-18-2
663903-19-3 663903-20-6 663903-21-7 663903-22-8 663903-23-9
663903-24-0 663903-25-1 663903-26-2 663903-27-3 663903-28-4
663903-29-5 663903-30-8 663903-31-9 663903-32-0 663903-33-1
663903-34-2 663903-35-3 ***663903-36-4*** 663903-37-5
663903-38-6 663903-39-7 663903-40-0 663903-41-1 663903-42-2
663903-43-3 663903-44-4 663903-45-5 663903-46-6 663903-47-7
663903-48-8 663903-49-9 663903-50-2 663903-51-3 663903-52-4
663903-53-5 663903-54-6 663903-55-7 663903-56-8 663903-57-9
663903-58-0 663903-59-1 663903-60-4 663903-61-5 663903-62-6
663903-63-7 663903-64-8 663903-65-9 663903-66-0 663903-67-1
663903-68-2 663903-69-3 663903-70-6 663903-71-7 663903-72-8
663903-73-9 663903-74-0 663903-75-1 663903-76-2 663903-82-0
663903-94-4 663903-95-5 663903-96-6 663904-09-4 663904-11-8
663904-12-9 663904-13-0 663904-14-1 663904-15-2 663904-18-5
663904-22-1 663904-23-2 663904-24-3 663904-25-4 663904-26-5
663904-27-6 663904-28-7 663904-29-8 663904-30-1 663904-32-3
663904-33-4 663904-34-5 663904-48-1 663904-49-2 663904-57-2
663904-58-3 663904-62-9 663904-91-4 663904-93-6 663905-46-2
663905-47-3 663905-48-4 663905-49-5 663905-50-8 663905-51-9
663905-52-0 663905-53-1 663905-54-2 663905-55-3 663905-56-4
663905-57-5 663905-58-6 663905-59-7 663905-60-0 663905-61-1
663905-62-2 663905-63-3 663905-64-4 663905-65-5 663905-66-6
663905-67-7 ***663905-68-8*** ***663905-69-9*** 663905-72-4
663905-75-7 663905-76-8 663905-78-0 663905-80-4 663905-81-5
663905-82-6 663905-83-7 663905-84-8 663905-85-9 663905-86-0
663905-87-1 663905-88-2 663905-89-3 663905-90-6 663905-91-7
663905-92-8 663905-93-9 663905-94-0 663905-95-1 663905-96-2
663905-97-3 663905-98-4 663905-99-5 663906-00-1 663906-01-2
663906-02-3

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
( ***cancer*** immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

IT 663906-03-4 ***663906-04-5*** 663906-05-6 663906-06-7
663906-07-8 663906-08-9 663906-09-0 663906-10-3 663906-11-4
663906-13-6 663906-14-7 663906-15-8 663906-16-9 663906-17-0
663906-18-1 663906-19-2 663906-20-5 663906-21-6 663906-22-7
663906-23-8 663906-25-0 663906-27-2 663906-29-4 663906-31-8
663906-32-9 663906-33-0 663906-34-1 663906-35-2 663906-36-3
663906-37-4 663906-38-5 663906-39-6 663906-40-9 663906-41-0
663906-42-1 663906-43-2 663906-44-3 663906-45-4 663906-46-5
663906-47-6 663906-48-7 663906-49-8 663906-50-1 663906-51-2
663906-52-3 663906-53-4 663906-54-5 663906-55-6 663906-56-7
663906-57-8 663906-59-0 663906-60-3 663906-61-4 663906-62-5
663906-63-6 663906-64-7 663906-65-8 663906-66-9 663906-67-0
663906-68-1 663906-69-2 663906-70-5 663906-71-6 663906-72-7
663906-73-8 663906-74-9 663906-75-0 663906-76-1 663906-77-2
663906-78-3 663906-79-4 663906-80-7 663906-81-8 663906-82-9
663906-83-0 663906-84-1 663906-85-2 663906-86-3 663906-87-4
663906-88-5 663906-89-6 663906-90-9 663906-91-0 663906-92-1
663906-93-2 663906-94-3 663906-95-4 663906-96-5 663906-97-6
663906-98-7 663906-99-8 663907-00-4 663907-01-5 663907-02-6

663907-03-7 663907-04-8 663907-05-9 663907-06-0 663907-07-1
663907-08-2 663907-09-3 663907-10-6 663907-11-7 663907-12-8
663907-16-2 663907-19-5 663907-22-0 663907-26-4 663907-30-0
663907-31-1 663907-32-2 663907-33-3 663907-34-4 663907-35-5
663907-36-6 663907-37-7 663907-38-8 663907-39-9 663907-40-2
663907-41-3 663907-42-4 663907-43-5 663907-44-6 663907-45-7
663907-46-8 663907-47-9 663907-48-0 663907-49-1 663907-50-4
663907-51-5 663907-52-6 663907-53-7 663907-54-8 663907-55-9
663907-56-0 663907-57-1 663907-58-2 663907-59-3 663907-60-6
663907-61-7 663907-62-8 663907-63-9 663907-64-0 663907-65-1
663907-66-2 663907-67-3 663907-68-4 663907-69-5 663907-70-8
663907-71-9 663907-72-0 663907-73-1 663907-74-2 663907-75-3
663907-76-4 663907-77-5 663907-78-6 663907-79-7 663907-80-0
663907-81-1 663907-82-2 663907-83-3 663907-84-4 663907-85-5
663907-86-6 663907-87-7 663907-88-8 663907-89-9 663907-90-2
663907-91-3 663907-92-4 663907-93-5 663907-94-6 663907-95-7
663907-96-8 663907-97-9 663907-98-0 663907-99-1 663908-00-7
663908-01-8 663908-02-9 663908-03-0 663908-04-1 663908-05-2
663908-06-3 663908-07-4 663908-08-5 663908-09-6 663908-10-9
663908-11-0 663908-12-1 663908-13-2 663908-14-3 663908-15-4
663908-16-5 663908-17-6 663908-18-7 663908-19-8 663908-20-1
663908-21-2 663908-22-3 663908-23-4 663908-24-5 663908-25-6
663908-26-7 663908-27-8 663908-28-9 663908-29-0 663908-30-3
663908-31-4 663908-32-5 663908-33-6 663908-34-7 663908-35-8
663908-36-9 663908-37-0 663908-38-1 663908-39-2 663908-40-5
663908-41-6 663908-42-7 663908-43-8 663908-44-9 663908-46-1
663908-47-2 663908-48-3 663908-49-4 663908-50-7 663908-51-8
663908-52-9 663908-53-0 663908-54-1 663908-55-2 663908-56-3
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
( ***cancer*** immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

IT 663908-57-4 663908-58-5 663908-59-6 663908-60-9 663908-61-0
663908-62-1 663908-63-2 663908-65-4 663908-67-6 663908-68-7
663908-69-8 663908-70-1 663908-72-3 663908-74-5 663908-76-7
663908-79-0 663908-81-4 663908-83-6 663908-85-8 663908-87-0
663908-88-1 663908-90-5 663908-92-7 663908-94-9 663908-95-0
663908-96-1 663908-98-3 663909-00-0 663909-01-1 663909-04-4
663909-07-7 663909-08-8 663909-10-2 663909-11-3 663909-13-5
663909-16-8 663909-19-1 663909-22-6 663909-24-8 663909-26-0
663909-29-3 663909-31-7 663909-32-8 663909-33-9 663909-34-0
663909-35-1 663909-36-2 663909-37-3 663909-38-4 663909-39-5
663909-40-8 663909-41-9 663909-42-0 663909-43-1 ***663909-44-2***
663909-45-3 663909-46-4 663909-47-5 663909-48-6 663909-49-7
663909-50-0 663909-51-1 663909-52-2 663909-53-3 663909-54-4
663909-55-5 663909-56-6 663909-57-7 663909-58-8 663909-59-9
663909-60-2 663909-61-3 663909-62-4 663909-63-5 663909-64-6
663909-65-7 663909-66-8 663909-67-9 663909-68-0 663909-69-1
663909-70-4 663909-71-5 663909-72-6 663909-73-7 663909-74-8
663909-75-9 663909-76-0 663909-77-1 663909-78-2 663909-79-3
663909-80-6 663909-83-9 663909-86-2 663909-89-5 663909-92-0
663909-95-3 663909-98-6 663910-00-7 663910-01-8
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
( ***cancer*** immunotherapy and diagnosis using immunogenic peptides from human cytochrome P 450 1B1)

L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:678462 CAPLUS
DOCUMENT NUMBER: 133:348838
TITLE: The B subunit of shiga toxin fused to a tumor antigen elicits CTL and ***targets*** dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens
AUTHOR(S): Haicheur, Nacilla; Bismuth, Emmanuelle; Bosset, Sophie; Adotevi, Olivier; Warnier, Guy; Lacabanne, Valerie; Regnault, Armelle; Desaymard, Catherine; Amigorena, Sebastian; Ricciardi-Castagnoli, Paola; Goud, Bruno; Fridman, Wolf H.; Johannes, Ludger; Tartour, Eric
CORPORATE SOURCE: Unite d'Immunologie Clinique, Institut de la Sante et de la Recherche Medicale, Unite 255, Universite Pierre et Marie Curie, Institut Curie, Paris, 75248, Fr.
SOURCE: Journal of Immunology (2000), 165(6), 3301-3308

CODEN: JOIMA3; ISSN: 0022-1767
PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI The B subunit of shiga toxin fused to a tumor antigen elicits CTL and ***targets*** dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens

AB Immunization with peptide or recombinant proteins generally fails to elicit CTL, which are thought to play a key role in the control of virus-infected cells and tumor growth. In this study we show that the nontoxic B subunit of Shiga toxin fused to a tumor peptide derived from the mouse mastocytoma P815 can induce specific CTL in mice without the use of adjuvant. The Shiga B subunit acts as a vector rather than as an adjuvant, because coinjection of the tumor peptide and the B subunit as sep. entities does not lead to CTL induction. We also demonstrated that in vitro the B subunit mediates the ***delivery*** of various exogenous CD8 T cell epitopes into the conventional MHC class I-restricted pathway, as this process is inhibited by brefeldin A and lactacystin and requires a functional TAP system. In contrast to other nonviral methods for transport of exogenous Ags into the endogenous MHC class I pathway that involve macropinocytosis or phagocytosis, the Shiga B subunit ***targets*** this pathway in a receptor-dependent manner, namely via binding to the glycolipid Gb3. Because this receptor is highly expressed on various dendritic cells, it should allow preferential ***targeting*** of the Shiga B subunit to these professional APCs. Therefore, the Shiga B subunit appears to represent an attractive vector for vaccine development due to its ability to ***target*** dendritic cells and to induce specific CTL without the need for adjuvant.

IT Antigen presentation
Dendritic cell
Genetic vectors
MHC restriction
(B subunit of Shiga toxin fused to a tumor antigen elicits CTL and ***targets*** dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens)

IT Toxins
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(Shiga, B subunit, fusion protein with tumor antigen; B subunit of Shiga toxin fused to a tumor antigen elicits CTL and ***targets*** dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(TAP-1 (transporter in antigen processing 1); B subunit of Shiga toxin fused to a tumor antigen elicits CTL and ***targets*** dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens and requirement for)

IT Immunostimulants
(adjuvants; B subunit of Shiga toxin fused to a tumor antigen elicits CTL and ***targets*** dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens in absence of)

IT T cell (lymphocyte)
(cytotoxic; B subunit of Shiga toxin fused to a tumor antigen elicits CTL and ***targets*** dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens)

IT 138831-86-4DP, fusion protein with Shiga toxin B subunit
***145882-36-6DP*** , fusion protein with Shiga toxin B subunit
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(B subunit of Shiga toxin fused to a ***tumor*** antigen elicits CTL and ***targets*** dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens)

IT 71965-57-6, Globotriaosylceramide
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(B subunit of Shiga toxin fused to a tumor antigen elicits CTL and ***targets*** dendritic cells to allow MHC class I-restricted

presentation of peptides derived from exogenous antigens via binding to)

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:549173 CAPLUS
DOCUMENT NUMBER: 131:175084
TITLE: Pharmaceutical formulation of a didemnin compound
INVENTOR(S): Beijnen, Jacob Hendrik; Nuyen, Bastiaan; Henrar, Roland Elizabeth Cornelis; Gomez, Andres; Jimeno, Jose
PATENT ASSIGNEE(S): Pharma Mar, S.A., Spain; Ruffles, Graham Keith
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9942125 | A1 | 19990826 | WO 1999-GB511 | 19990218 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2321116 | AA | 19990826 | CA 1999-2321116 | 19990218 |
| AU 9925389 | A1 | 19990906 | AU 1999-25389 | 19990218 |
| AU 754073 | B2 | 20021107 | | |
| BR 9908088 | A | 20001031 | BR 1999-8088 | 19990218 |
| EP 1054686 | A1 | 20001129 | EP 1999-905091 | 19990218 |
| EP 1054686 | B1 | 20020515 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2002503704 | T2 | 20020205 | JP 2000-532139 | 19990218 |
| AT 217532 | E | 20020615 | AT 1999-905091 | 19990218 |
| PT 1054686 | T | 20020930 | PT 1999-905091 | 19990218 |
| ES 2175940 | T3 | 20021116 | ES 1999-905091 | 19990218 |
| HK 1032538 | A1 | 20021206 | HK 2001-103194 | 20010507 |

PRIORITY APPLN. INFO.: GB 1998-3448 A 19980218
WO 1999-GB511 W 19990218
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE F
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT Drug ***delivery*** systems
(parenterals, freeze-dried; lyophilized parenteral pharmaceuticals contg. didemnin compds. for cancer treatment)
IT 69-65-8, D-Mannitol 110342-52-4, Didemnin ***137219-37-5*** , Aplidine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lyophilized parenteral pharmaceuticals contg. didemnin compds. for ***cancer*** treatment)

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:123663 CAPLUS
DOCUMENT NUMBER: 130:310353
TITLE: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
AUTHOR(S): Toda, Masahiro; Rabkin, Samuel D.; Kojima, Hidefumi; Martuza, Robert L.
CORPORATE SOURCE: Georgetown Brain Tumor Center and Department of Neurosurgery, Georgetown University Medical Center, Washington, DC, 20007, USA
SOURCE: Human Gene Therapy (1999), 10(3), 385-393
CODEN: HGTHE3; ISSN: 1043-0342
PUBLISHER: Mary Ann Liebert, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB The success of cancer gene therapy is likely to require the ***targeting*** of multiple antitumor mechanisms. One strategy involves

the use of attenuated, replication-competent virus vectors, such as herpes simplex virus type 1 (HSV-1) mutant G207, which is able to replicate in human tumor cells with resultant cell death and tumor growth inhibition, yet is nonpathogenic in normal tissue. In this study, we demonstrate that infection of established tumors with G207 also induces a highly specific systemic anti-tumor immune response. In a syngeneic, bilateral established s.c. tumor model, with mouse CT26 colorectal carcinoma cells in BALB/c mice or M3 melanoma cells in DBA/2 mice, unilateral intratumoral inoculation with G207 caused a significant redn. in the growth of both the inoculated and contralateral noninoculated tumors. This elicited anti-tumor response is dependent on viral infection of the tumor, as intradermal inoculation of G207 in BALB/c mice had no effect on CT26 tumor growth. Treatment of s.c. CT26 tumors by intratumoral inoculation of G207 induced a tumor-specific T cell response. CD8+ cytotoxic T lymphocyte (CTL) activity was generated that recognized a dominant "tumor-specific" major histocompatibility complex (MHC) class I-restricted epitope (AH1) from CT26 cells. In immune-competent animals, G207 is acting as an in situ tumor vaccine. Therefore, intratumoral G207 inoculation is able to inhibit tumor growth both by local cytotoxic viral replication in tumor cells and induction of a systemic anti-tumor immune response.

IT ***145882-36-6P***
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(herpes simplex virus as an in situ ***cancer*** vaccine for induction of specific anti- ***tumor*** immunity and recognition of mastocytoma P815 antigenic peptide)

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:13451 CAPLUS
DOCUMENT NUMBER: 130:236141
TITLE: Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
AUTHOR(S): Fallarino, Francesca; Uyttenhove, Catherine; Boon, Thierry; Gajewskii, Thomas F.
CORPORATE SOURCE: Department of Pathology, University of Chicago, Chicago, IL, USA
SOURCE: International Journal of Cancer (1999), 80(2), 324-333
CODEN: IJCNAW; ISSN: 0020-7136
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The well-characterized P815 tumor model was used to optimize anti-tumor immunization approaches in mice. Tumor peptides derived from antigens P198 or P1A were ***targeted*** to antigen-presenting cells (APC) by ex vivo pulsing. Initial expts. with irradiated pulsed splenic dendritic cells (sDC) injected weekly in the hind footpads for 3 wk demonstrated cytolytic T lymphocyte (CTL) generation in 10-20% of mice. Because of the importance of interleukin-12 (IL-12) in tumor rejection responses, pulsed sDCs also were given together with recombinant murine IL-12 (rmIL-12). This strategy induced peptide-specific CTL in 100% of the mice. The IL-12 had to be injected in the footpads on days 0, 1 and 2 of each immunization week to achieve an optimal effect. The improvement seen with the addn. of IL-12 prompted examn. of other sources of APC. Purified resting B cells, lipopolysaccharide (LPS) blasts and non-fractionated splenocytes or peripheral blood mononuclear cells (PBMC) were pulsed with peptide and administered with the same schedule of rmIL-12. Because these cell types appeared to bind peptides less avidly than did DC, increasing peptide doses were used during pulsing. Interestingly, immunization with each of these APC also induced specific CTL in 100% of mice, provided rmIL-12 was coadministered. CTLs were detected both in the spleen and in the peripheral blood. Immunization with irradiated, P1A-pulsed PBMC plus rmIL- 12 resulted in protection against challenge with tumors expressing the specific antigen in all mice. The ease by which human patient PBMCs can be prepd. provides a straightforward vaccination approach to be used in clin. trials of peptide-based immunization in melanoma.

IT 136671-85-7P ***145882-36-6P***
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(dendritic cell vaccines and immunization with ***tumor*** antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12)

L9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:531867 CAPLUS
DOCUMENT NUMBER: 123:74098
TITLE: Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen
AUTHOR(S): Alvarez, Manuel; Paull, Ken; Monks, Anne; Hose, Curtis; Lee, Jong-Seok; Weinstein, John; Grever, Mike; Bates, Susan; Fojo, Tito
CORPORATE SOURCE: Lab. Mol. Pharmacol., Developmtl. Therapeutics Program, National Cancer Institute, National Institutes Health, Bethesda, MD, 20892, USA
SOURCE: Journal of Clinical Investigation (1995), 95(5), 2205-14
CODEN: JCINAO; ISSN: 0021-9738
PUBLISHER: Rockefeller University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Identifying new chemotherapeutic agents and characterizing mechanisms of resistance may improve cancer treatment. The Anticancer Drug Screen of the National Cancer Institute uses 60 cell lines to identify new agents. Expression of mdr-1/P-glycoprotein was measured by quant. PCR. Expression was detected in 39 cell lines; the highest levels were in renal and colon carcinomas. Expression was also detected in all melanomas and central nervous system tumors, but in only one ovarian carcinoma and one leukemia cell line. Using a modified version of the COMPARE program, a high correlation was found between expression of mdr-1 and cellular resistance to a large no. of compds. Evidence that these compds. are P-glycoprotein substrates includes: (a) enhancement of cytotoxicity by verapamil; (b) demonstration of cross-resistance in a multidrug-resistant cell line, (c) ability to antagonize P-glycoprotein, increasing vinblastine accumulation by decreasing efflux; and (d) inhibition of photoaffinity labeling by azidopine. Identification of many heretofore unrecognized compds. as substrates indicates that P-glycoprotein has a broader substrate specificity than previously recognized. This study confirms the validity of this novel approach and provides the basis for similar studies examg. a diverse group of gene products, including other resistance mechanisms, putative drug ***targets*** , and genes involved in the cell cycle and apoptosis.
IT 50-44-2, 6-Mercaptopurine 50-76-0, Actinomycin D 51-21-8, 5-Fluorouracil 52-24-4, Thiotepa 52-53-9, Verapamil 55-86-7, Nitrogen mustard 59-05-2, Methotrexate 127-07-1, Hydroxyurea 147-94-4, Cytosine arabinoside 148-82-3, Melphalan 154-93-8, BCNU 305-03-3, Chlorambucil 512-64-1, NSC 526417 865-21-4, Vinblastine 5853-29-2, (-)-Cephaeline dihydrochloride 7059-24-7, Chromomycin A3 11006-70-5, Olivomycin 13010-47-4, CCNU 15663-27-1, Cisplatinum 20830-81-3, Daunomycin 25316-40-9, Adriamycin 29767-20-2, VM-26 33069-62-4, Taxol 33419-42-0, VP-16 41451-75-6, Bruceantin 51264-14-3, Amsacrine 53142-03-3, NSC 646428 62816-98-2, Tetraplatin 63166-73-4, Phyllanthoside 63521-85-7 64725-24-2, Deoxybouvardin 64755-14-2, Bouvardin 65548-52-9, NSC 649087 71439-68-4, Bisantrene hydrochloride ***77327-05-0*** , NSC 325319 80790-68-7 81552-36-5, Trioxacarcin A 86825-99-2 88254-07-3 110417-88-4, NSC 376128 123830-79-5, NSC 355644 130760-07-5, NSC 624332 131251-67-7, NSC 633320 133091-36-8, NSC 626852 153264-95-0 160262-47-5, NSC 640085 160338-75-0, NSC 172946 165169-10-8, NSC 80467 165169-11-9, NSC 353076 165169-12-0, NSC 620308 165169-13-1, NSC 637905 165169-14-2, NSC 645806 165169-15-3, NSC 648785 165198-36-7, NSC 648114 165198-37-8, NSC 346243 165198-38-9, NSC 626316 165198-39-0, NSC 344003 165290-33-5, NSC 643179
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National ***Cancer*** Institute Anticancer Drug Screen)

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:519394 CAPLUS

DOCUMENT NUMBER: 122:263156
TITLE: Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL
AUTHOR(S): Irvine, Kari R.; McCabe, Barbra Jill; Rosenberg, Steven A.; Restifo, Nicholas P.
CORPORATE SOURCE: Surgery Branch, Natl. Inst. Health, Bethesda, MD, 20892, USA
SOURCE: Journal of Immunology (1995), 154(9), 4651-7
CODEN: JOIMA3; ISSN: 0022-1767
PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English
IT Antigens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p815A; tumor rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum- ***targeted*** peptide of)
IT Endoplasmic reticulum
Vaccines
(tumor rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum- ***targeted*** peptide of tumor-assocd. antigen)
IT Histocompatibility antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MHC (major histocompatibility antigen complex), class I, tumor rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum- ***targeted*** peptide of tumor-assocd. antigen)
IT Lymphocyte
(T-cell, cytotoxic, vaccinia virus encoding endoplasmic reticulum- ***targeted*** tumor-assocd. antigenic peptide induces tumor rejection by)
IT Antigens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor-assocd., tumor rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum- ***targeted*** peptide of)
IT Virus, animal
(vaccinia, tumor rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum- ***targeted*** peptide of tumor-assocd. antigen)
IT ***145882-36-6***
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
( ***tumor*** rejection by cytotoxic T-cells is induced by vaccinia virus encoding endoplasmic reticulum- ***targeted*** peptide of ***tumor*** -assocd. antigen)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | SESSION | TOTAL |
|---|---|---|---|
| FULL ESTIMATED COST | | 51.43 | 85.29 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | SESSION | TOTAL |
|---|---|---|---|
| CA SUBSCRIBER PRICE | | -3.75 | -3.75 |

STN INTERNATIONAL LOGOFF AT 11:50:35 ON 18 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist $500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhancec
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

***COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31***

***Dear valued STN customer,***

***In an effort to enhance your experience with STN, we would***
***like to better understand what you find useful. Please take***
***approximately 5 minutes to complete a web survey.***

***If you provide us with your name, login ID, and e-mail address, you***
***will be entered in a drawing to win a free iPod(R). Your responses***
***will be kept confidential and will help us make future improvements***
***to STN.***

***Take survey: http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW ***

***Thank you in advance for your participation.***

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:42:48 ON 18 MAY 2006

=> file reg
COST IN U.S. DOLLARS                      SINCE FILE     TOTAL
                                            ENTRY    SESSION
FULL ESTIMATED COST                            0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:42:56 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:  16 MAY 2006  HIGHEST RN 884586-69-0
DICTIONARY FILE UPDATES:  16 MAY 2006  HIGHEST RN 884586-69-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                       *
*************************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s LPY/SQSP
L1     159373 LPY/SQSP

=> s l1 and SQL=<100
     9239723 SQL=<100
L2       9302 L1 AND SQL=<100

=> s 137219-37-5 or 663892-58-8 or 663892-97-5 or 663894-35-7 or 663895-27-0
           1 137219-37-5
             (137219-37-5/RN)
           1 663892-58-8
             (663892-58-8/RN)
           1 663892-97-5
             (663892-97-5/RN)
           1 663894-35-7
             (663894-35-7/RN)
           1 663895-27-0
             (663895-27-0/RN)
L3         5 137219-37-5 OR 663892-58-8 OR 663892-97-5 OR 663894-35-7 OR
           663895-27-0

=> s l2 and l3
L4         5 L2 AND L3

=> d sql seq 1-5

L4  ANSWER 1 OF 5  REGISTRY  COPYRIGHT 2006 ACS on STN
SQL   ***9***
```

```
SEQ     1 PNLPYVLAF
          ===
HITS AT:  3-5

L4  ANSWER 2 OF 5  REGISTRY  COPYRIGHT 2006 ACS on STN
SQL   ***9***

SEQ     1 DQPNLPYVL
           ===
HITS AT:  5-7

L4  ANSWER 3 OF 5  REGISTRY  COPYRIGHT 2006 ACS on STN
SQL   ***9***

SEQ     1 GDQPNLPYV
           ===
HITS AT:  6-8

L4  ANSWER 4 OF 5  REGISTRY  COPYRIGHT 2006 ACS on STN
SQL   ***9***

SEQ     1 NLPYVLAFL
          ===
HITS AT:  2-4

L4  ANSWER 5 OF 5  REGISTRY  COPYRIGHT 2006 ACS on STN
SQL   ***8***

SEQ     1 PLTXXLPY
           ===
HITS AT:  6-8

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**


=> d cn sql seq 1-5

L4  ANSWER 1 OF 5  REGISTRY  COPYRIGHT 2006 ACS on STN
CN  L-Phenylalanine, L-prolyl-L-asparaginyl-L-leucyl-L-prolyl-L-tyrosyl-L-
    valyl-L-leucyl-L-alanyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN  26: PN: WO0135810 SEQID: 276 claimed protein
SQL   ***9***

SEQ     1 PNLPYVLAF
          ===
HITS AT:  3-5

L4  ANSWER 2 OF 5  REGISTRY  COPYRIGHT 2006 ACS on STN
CN  L-Leucine, L-.alpha.-aspartyl-L-glutaminyl-L-prolyl-L-asparaginyl-L-leucyl-
    L-prolyl-L-tyrosyl-L-valyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN  51: PN: WO0135810 SEQID: 184 claimed protein
SQL   ***9***

SEQ     1 DQPNLPYVL
           ===
HITS AT:  5-7

L4  ANSWER 3 OF 5  REGISTRY  COPYRIGHT 2006 ACS on STN
CN  L-Valine, glycyl-L-.alpha.-aspartyl-L-glutaminyl-L-prolyl-L-asparaginyl-L-
    leucyl-L-prolyl-L-tyrosyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN  6: PN: WO0135810 SEQID: 46 claimed protein
SQL   ***9***

SEQ     1 GDQPNLPYV
           ===
HITS AT:  6-8

L4  ANSWER 4 OF 5  REGISTRY  COPYRIGHT 2006 ACS on STN
CN  L-Leucine, L-asparaginyl-L-leucyl-L-prolyl-L-tyrosyl-L-valyl-L-leucyl-L-
    alanyl-L-phenylalanyl- (9CI)  (CA INDEX NAME)
```

OTHER NAMES:
CN 7: PN: WO0135810 SEQID: 6 claimed protein
SQL ***9***

SEQ 1 NLPYVLAFL
===
HITS AT: 2-4

L4 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2006 ACS on STN
CN Didemnin A, N-[1-(1,2-dioxopropyl)-L-prolyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 15H-Pyrrolo[2,1-f][1,15,4,7,10,20]dioxatetraazacyclotricosine, cyclic peptide deriv.
OTHER NAMES:
CN Aplidin
CN Aplidine
CN Dehydrodidemnin B
CN Plitidepsin
SQL ***8***

SEQ 1 PLTXXLPY
===
HITS AT: 6-8

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | ENTRY | SINCE FILE SESSION | TOTAL |
|---|---|---|---|
| FULL ESTIMATED COST | | 93.77 | 93.98 |

STN INTERNATIONAL LOGOFF AT 13:45:31 ON 18 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

********** Welcome to STN International **********

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC

thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist $500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhancec
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

***COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31***

***Dear valued STN customer,***

***In an effort to enhance your experience with STN, we would***
***like to better understand what you find useful. Please take***
***approximately 5 minutes to complete a web survey.***

***If you provide us with your name, login ID, and e-mail address, you***
***will be entered in a drawing to win a free iPod(R). Your responses***
***will be kept confidential and will help us make future improvements***
***to STN.***

***Take survey: http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW ***

***Thank you in advance for your participation.***

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:06:21 ON 18 MAY 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 14:06:30 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6
DICTIONARY FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

```
**************************************************************************
*                                                                        *
* The CA roles and document type information have been removed from      *
* the IDE default display format and the ED field has been added,        *
* effective March 20, 2005.  A new display format, IDERL, is now         *
* available and contains the CA role and document type information.      *
*                                                                        *
**************************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> s lpy/SQSP
L1     159373 LPY/SQSP

=> s l1 and SQL=<20
     3919358 SQL=<20
L2       1357 L1 AND SQL=<20

=> file caplus
COST IN U.S. DOLLARS                        SINCE FILE     TOTAL
                                   ENTRY    SESSION
FULL ESTIMATED COST                            33.65     33.86

FILE 'CAPLUS' ENTERED AT 14:07:15 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 18 May 2006  VOL 144 ISS 21
FILE LAST UPDATED: 17 May 2006  (20060517/ED)
```

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l2
L3         881 L2

=> s cancer? or tumor? or neoplas?
       292904 CANCER?
       427701 TUMOR?
       449273 NEOPLAS?
L4     708462 CANCER? OR TUMOR? OR NEOPLAS?

=> s l3 (l) l4
L5         127 L3 (L) L4

=> s liposom?
L6      50046 LIPOSOM?

=> s l6 and l5
L7          8 L6 AND L5
```

```
=> s l7 not py>2002
     3859922 PY>2002
L8         0 L7 NOT PY>2002

=> s l3 and l4
L9       312 L3 AND L4

=> s l9 and l6
L10       21 L9 AND L6

=> s l10 not py>2002
     3859922 PY>2002
L11        1 L10 NOT PY>2002

=> d ibib

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       1999:511054 CAPLUS
DOCUMENT NUMBER:        131:149319
TITLE:                  ***Liposome*** fusion and delivery vehicle
INVENTOR(S):            Longmuir, Kenneth J.; Waring, Alan J.; Haynes, Sherry
                  M.
PATENT ASSIGNEE(S):     USA
SOURCE:                 PCT Int. Appl., 47 pp.
                  CODEN: PIXXD2
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

    PATENT NO.        KIND  DATE       APPLICATION NO.      DATE
    --------------    ----  --------   -------------------  --------
    WO 9939742        A1    19990812   WO 1999-US2410       19990204
      W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
         DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
         KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
         MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
         TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
         TJ, TM
      RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
         FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
         CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    US 6372720        B1    20020416   US 1998-19346        19980205
    CA 2325744        AA    19990812   CA 1999-2325744      19990204
    AU 9925823        A1    19990823   AU 1999-25823        19990204
    EP 1053024        A1    20001122   EP 1999-905726       19990204
      R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
         IE, FI
PRIORITY APPLN. INFO.:                  US 1998-19346     A  19980205
                                  WO 1999-US2410    W  19990204
REFERENCE COUNT:        7    THERE ARE 7 CITED REFERENCES AVAILABLE FO
                      RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d kwic

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI   ***Liposome*** fusion and delivery vehicle
AB   Described herein are ***liposome*** complexes and the individual
     components thereof for intracellular and/or intranuclear delivery of
     substances. Methods of use of the provided ***liposome*** complexes
     and components are also described. Generally, the ***liposome***
     complexes described herein include a non-cationic lipid, a fusogenic
     peptide and a substance to be delivered to the cell and/or nucleus. In
     some of the ***liposome*** complexes described herein, the fusogenic
     peptide does not contain multiple pos. charges at neutral pH and above.
     In these ***liposome*** complexes, two addnl. components are used in
     assembling the ***liposome*** complex with DNA.
ST   pharmaceutical ***liposome*** nucleic acid cell delivery;
     ***tumor*** cell targeting pharmaceutical ***liposome***
IT   Pulmonary surfactant
     (B peptide; ***liposome*** complexes and individual components
     thereof for intracellular and/or intranuclear delivery of substances)
```

IT Plasmids
(DNA; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT ***Neoplasm***
(cells; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT Embryo, animal
(chick; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT ***Liposomes***
(complexes, for intracellular and/or intranuclear delivery; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(for luciferase, expression of; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT Peptides, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(fusogenic; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT Animal cell
Cell nucleus
Cytoplasm
( ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT Nucleic acids
Polyoxyalkylenes, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
( ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT DNA
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
( ***liposome*** complexes with; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT Drug delivery systems
( ***liposomes*** , for cell targeting; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT Lipids, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(noncationic; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT Phospholipids, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(zwitterionic or anionic; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT 9014-00-0, Luciferase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(gene for, expression of; ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)
IT 4004-05-1, Dioleoylphosphatidylethanolamine 4235-95-4 25322-68-3 56750-90-4 125056-56-6 236093-94-0 236093-95-1 236093-96-2 236093-97-3 236093-98-4 236093-99-5 236094-00-1 236094-01-2 ***236094-02-3*** 236094-04-5 236094-05-6 236094-06-7
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
( ***liposome*** complexes and individual components thereof for intracellular and/or intranuclear delivery of substances)

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

```
                                                ENTRY    SESSION
FULL ESTIMATED COST                                16.61     50.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE     TOTAL
                                                ENTRY    SESSION
CA SUBSCRIBER PRICE                                -0.75     -0.75

FILE 'REGISTRY' ENTERED AT 14:09:37 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:  17 MAY 2006  HIGHEST RN 884739-24-6
DICTIONARY FILE UPDATES:  17 MAY 2006  HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                       *
*************************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s 236094-02-3
L12          1 236094-02-3
             (236094-02-3/RN)

=> d his

    (FILE 'HOME' ENTERED AT 14:06:21 ON 18 MAY 2006)

    FILE 'REGISTRY' ENTERED AT 14:06:30 ON 18 MAY 2006
L1      159373 S LPY/SQSP
L2        1357 S L1 AND SQL=<20

    FILE 'CAPLUS' ENTERED AT 14:07:15 ON 18 MAY 2006
L3         881 S L2
L4      708462 S CANCER? OR TUMOR? OR NEOPLAS?
L5         127 S L3 (L) L4
L6       50046 S LIPOSOM?
L7           8 S L6 AND L5
L8           0 S L7 NOT PY>2002
L9         312 S L3 AND L4
L10         21 S L9 AND L6
L11          1 S L10 NOT PY>2002

    FILE 'REGISTRY' ENTERED AT 14:09:37 ON 18 MAY 2006
L12          1 S 236094-02-3

=> s l12 and l2
L13          1 L12 AND L2

=> d en sql scq
```

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
CN L-Histidinamide, L-phenylalanyl-L-prolyl-L-isoleucyl-L-prolyl-L-leucyl-L-prolyl-L-tyrosyl-L-alanyl-L-tryptophyl-L-leucyl-L-cysteinylglycyl-L-lysyl-L-lysyl-L-lysyl-L-phenylalanyl-L-lysyl-L-leucyl-L-lysyl- (9CI) (CA INDEX NAME)
SQL ***20***

SEQ 1 FPIPLPYAWL CGKKKFKLKH
===
HITS AT: 5-7

=>

=>
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 7.24 57.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -0.75

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 14:11:03 ON 18 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 14:48:11 ON 18 MAY 2006
FILE 'REGISTRY' ENTERED AT 14:48:11 ON 18 MAY 2006
COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 7.24 57.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -0.75

=> d his

(FILE 'HOME' ENTERED AT 14:06:21 ON 18 MAY 2006)

FILE 'REGISTRY' ENTERED AT 14:06:30 ON 18 MAY 2006
L1 159373 S LPY/SQSP
L2 1357 S L1 AND SQL=<20

FILE 'CAPLUS' ENTERED AT 14:07:15 ON 18 MAY 2006
L3 881 S L2
L4 708462 S CANCER? OR TUMOR? OR NEOPLAS?
L5 127 S L3 (L) L4
L6 50046 S LIPOSOM?
L7 8 S L6 AND L5
L8 0 S L7 NOT PY>2002
L9 312 S L3 AND L4
L10 21 S L9 AND L6
L11 1 S L10 NOT PY>2002

```
   FILE 'REGISTRY' ENTERED AT 14:09:37 ON 18 MAY 2006
L12         1 S 236094-02-3
L13         1 S L12 AND L2

=> s l10 not py>2003
'2003' NOT A VALID FIELD CODE
      15897 CANCER?
     348992 TUMOR?
       5424 NEOPLAS?
          3 LIPOSOM?
          0 PY>2003
L14         0 L10 NOT PY>2003

=> file caplus
COST IN U.S. DOLLARS                        SINCE FILE     TOTAL
                                   ENTRY    SESSION
FULL ESTIMATED COST                            26.72      77.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE     TOTAL
                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                             0.00      -0.75

FILE 'CAPLUS' ENTERED AT 14:49:03 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 May 2006  VOL 144 ISS 21
FILE LAST UPDATED: 17 May 2006  (20060517/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l10 not py>2003
     2790637 PY>2003
L15         3 L10 NOT PY>2003

=> d ibib 1-3

L15  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2003:950032  CAPLUS
DOCUMENT NUMBER:         140:19766
TITLE:                   Compositions containing the SP(1-4) polypeptide, or
                         NEP antisense sequences and antibodies, and methods
                         for the regulation of proliferation of stem cells
INVENTOR(S):             Rameshwar, Pranela
PATENT ASSIGNEE(S):      University of Medicine & Dentistry of New Jersey, USA
SOURCE:                  U.S. Pat. Appl. Publ., 42 pp.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

    PATENT NO.          KIND  DATE       APPLICATION NO.      DATE
    --------------      ----  --------   -------------------  --------
    US 2003225010       A1    20031204   US 2002-154332       20020521
PRIORITY APPLN. INFO.:                   US 2002-154332       20020521

L15  ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2001:12285  CAPLUS
```

DOCUMENT NUMBER: 134:99563
TITLE: HLA binding peptides and their uses
INVENTOR(S): Sette, Alessandro; Sidney, John; Southwood, Scott
PATENT ASSIGNEE(S): Epimmune Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001000225 | A1 | 20010104 | WO 2000-US17842 | 20000628 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2370413 | AA | 20010104 | CA 2000-2370413 | 20000628 |
| EP 1189624 | A1 | 20020327 | EP 2000-944976 | 20000628 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| JP 2003535024 | T2 | 20031125 | JP 2001-505934 | 20000628 |

PRIORITY APPLN. INFO.: US 1999-141422P P 19990629
WO 2000-US17842 W 20000628
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE F(
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:511054 CAPLUS
DOCUMENT NUMBER: 131:149319
TITLE: ***Liposome*** fusion and delivery vehicle
INVENTOR(S): Longmuir, Kenneth J.; Waring, Alan J.; Haynes, Sherry M.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9939742 | A1 | 19990812 | WO 1999-US2410 | 19990204 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6372720 | B1 | 20020416 | US 1998-19346 | 19980205 |
| CA 2325744 | AA | 19990812 | CA 1999-2325744 | 19990204 |
| AU 9925823 | A1 | 19990823 | AU 1999-25823 | 19990204 |
| EP 1053024 | A1 | 20001122 | EP 1999-905726 | 19990204 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |

PRIORITY APPLN. INFO.: US 1998-19346 A 19980205
WO 1999-US2410 W 19990204
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE F(
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION

```
FULL ESTIMATED COST                                  6.29     83.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE     TOTAL
                                                   ENTRY   SESSION
CA SUBSCRIBER PRICE                                  0.00     -0.75

FILE 'REGISTRY' ENTERED AT 14:50:14 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:  17 MAY 2006  HIGHEST RN 884739-24-6
DICTIONARY FILE UPDATES:  17 MAY 2006  HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**************************************************************************
*                                                                        *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                        *
**************************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d his

    (FILE 'HOME' ENTERED AT 14:06:21 ON 18 MAY 2006)

    FILE 'REGISTRY' ENTERED AT 14:06:30 ON 18 MAY 2006
L1      159373 S LPY/SQSP
L2        1357 S L1 AND SQL=<20

    FILE 'CAPLUS' ENTERED AT 14:07:15 ON 18 MAY 2006
L3         881 S L2
L4      708462 S CANCER? OR TUMOR? OR NEOPLAS?
L5         127 S L3 (L) L4
L6       50046 S LIPOSOM?
L7           8 S L6 AND L5
L8           0 S L7 NOT PY>2002
L9         312 S L3 AND L4
L10         21 S L9 AND L6
L11          1 S L10 NOT PY>2002

    FILE 'REGISTRY' ENTERED AT 14:09:37 ON 18 MAY 2006
L12          1 S 236094-02-3
L13          1 S L12 AND L2
L14          0 S L10 NOT PY>2003

    FILE 'CAPLUS' ENTERED AT 14:49:03 ON 18 MAY 2006
L15          3 S L10 NOT PY>2003

    FILE 'REGISTRY' ENTERED AT 14:50:14 ON 18 MAY 2006

=> s l1 and SQL=<30
     5932094 SQL=<30
```

```
L16      1681 L1 AND SQL=<30

=> s l16 and l2
L17      1357 L16 AND L2

=> s l16 not l2
L18       324 L16 NOT L2

=> file caplus
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                          ENTRY    SESSION
FULL ESTIMATED COST                          5.64      89.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                          ENTRY    SESSION
CA SUBSCRIBER PRICE                          0.00      -0.75

FILE 'CAPLUS' ENTERED AT 14:51:12 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 May 2006  VOL 144 ISS 21
FILE LAST UPDATED: 17 May 2006  (20060517/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l18
L19      225 L18

=> s l19 and l4
L20       41 L19 AND L4

=> s l20 and l6
L21        1 L20 AND L6

=> d ibib

L21  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       1999:511054  CAPLUS
DOCUMENT NUMBER:        131:149319
TITLE:                  ***Liposome***  fusion and delivery vehicle
INVENTOR(S):            Longmuir, Kenneth J.; Waring, Alan J.; Haynes, Sherry
                  M.
PATENT ASSIGNEE(S):     USA
SOURCE:                 PCT Int. Appl., 47 pp.
                  CODEN: PIXXD2
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

    PATENT NO.        KIND  DATE       APPLICATION NO.       DATE
    ---------------   ----  --------   -------------------   --------
    WO 9939742        A1    19990812   WO 1999-US2410        19990204
      W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
         DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
         KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
         MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
         TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
```

TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 6372720 | B1 | 20020416 | US 1998-19346 | 19980205 |
| CA 2325744 | AA | 19990812 | CA 1999-2325744 | 19990204 |
| AU 9925823 | A1 | 19990823 | AU 1999-25823 | 19990204 |
| EP 1053024 | A1 | 20001122 | EP 1999-905726 | 19990204 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.: US 1998-19346 A 19980205
WO 1999-US2410 W 19990204

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE F(
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 2.06 | 91.18 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | 0.00 | -0.75 |

STN INTERNATIONAL LOGOFF AT 14:52:26 ON 18 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist $500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhancec
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS 16 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

***COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31***

***Dear valued STN customer,***

***In an effort to enhance your experience with STN, we would***
***like to better understand what you find useful. Please take***
***approximately 5 minutes to complete a web survey.***

***If you provide us with your name, login ID, and e-mail address, you***
***will be entered in a drawing to win a free iPod(R). Your responses***
***will be kept confidential and will help us make future improvements***
***to STN.***

***Take survey: http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW ***

***Thank you in advance for your participation.***

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:07:17 ON 18 MAY 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 16:07:25 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6
DICTIONARY FILE UPDATES: 17 MAY 2006 HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

**********
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *

```
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s lpy/SQSP
L1     159373 LPY/SQSP

=> file caplus
COST IN U.S. DOLLARS                        SINCE FILE     TOTAL
                                   ENTRY    SESSION
FULL ESTIMATED COST                            28.89     29.10

FILE 'CAPLUS' ENTERED AT 16:07:44 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 May 2006  VOL 144 ISS 21
FILE LAST UPDATED: 17 May 2006  (20060517/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l1
L2      21611 L1

=> s cancer? or tumor? or neoplas?
      292904 CANCER?
      427701 TUMOR?
      449273 NEOPLAS?
L3     708462 CANCER? OR TUMOR? OR NEOPLAS?

=> s l2 and l3
L4       3097 L2 AND L3

=> s l2 (l) l3
L5        976 L2 (L) L3

=> s liposom?
L6       50046 LIPOSOM?

=> s l5 and l6
L7         21 L5 AND L6

=> s chemother? or (anticancer or (anti (2W) cancer))
       76841 CHEMOTHER?
       35080 ANTICANCER
          46 ANTICANCERS
       35100 ANTICANCER
             (ANTICANCER OR ANTICANCERS)
      406221 ANTI
```

```
        9 ANTIS
      406228 ANTI
             (ANTI OR ANTIS)
      278734 CANCER
       40530 CANCERS
      289315 CANCER
             (CANCER OR CANCERS)
        6337 ANTI (2W) CANCER
L8     110362 CHEMOTHER? OR (ANTICANCER OR (ANTI (2W) CANCER))

=> s l8 and l7
L9          2 L8 AND L7

=> d ibib 1-2

L9  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:193397  CAPLUS
DOCUMENT NUMBER:         144:272644
TITLE:                   Anti-mortalin 2 antibody and functional ribonucleic
                         acids for treating cancer
INVENTOR(S):             Kaul, Renuwadhwa; Taira, Kazunari; Kaul, Sunil
PATENT ASSIGNEE(S):      National Institute of Advanced Industrial Scienceand
                         Technology, Japan
SOURCE:                  PCT Int. Appl., 79 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                Japanese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

    PATENT NO.         KIND   DATE       APPLICATION NO.       DATE
    ---------------    ----   --------   --------------------  --------
    WO 2006022344      A1     20060302   WO 2005-JP15459       20050825
       W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
          CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
          GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KP, KR, KZ, LC,
          LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG,
          NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
          SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
          ZM, ZW
       RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
          IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
          CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
          GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
          KG, KZ, MD, RU, TJ, TM
    JP 2006089471      A2     20060406   JP 2005-242063        20050824
PRIORITY APPLN. INFO.:                   JP 2004-246891     A  20040826
                                         JP 2005-242063     A  20050824
REFERENCE COUNT:         11    THERE ARE 11 CITED REFERENCES AVAILABLE
                         RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2002:220814  CAPLUS
DOCUMENT NUMBER:         136:259587
TITLE:                   Novel tumor-associated marker
INVENTOR(S):             Trakht, Ilya; Canfield, Robert; Kalantarov, Gary;
                         Rudchenko, Sergei
PATENT ASSIGNEE(S):      The Trustees of Columbia University in the City of New
                         York, USA
SOURCE:                  PCT Int. Appl., 276 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

    PATENT NO.         KIND   DATE       APPLICATION NO.       DATE
    ---------------    ----   --------   --------------------  --------
    WO 2002022851      A2     20020321   WO 2001-US29242       20010918
    WO 2002022851      A3     20030501
       W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
          CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
          GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
          LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
```

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| CA 2422828 | AA | 20020321 | CA 2001-2422828 | 20010918 |
| AU 2001092782 | A5 | 20020326 | AU 2001-92782 | 20010918 |
| EP 1326894 | A2 | 20030716 | EP 2001-973176 | 20010918 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

| | | | | |
|---|---|---|---|---|
| JP 2004518630 | T2 | 20040624 | JP 2002-527293 | 20010918 |

PRIORITY APPLN. INFO.: US 2000-664958 A 20000918
WO 2001-US29242 W 20010918

=> d kwic 2

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
IT Drug delivery systems
( ***liposomes*** ; novel tumor-assocd. marker)
IT AIDS (disease)
Animal tissue
Apoptosis
Ascitic fluid
Autoimmune disease
Bacteremia
Blood analysis
Blood plasma
Blood serum
Bone marrow
Cerebrospinal fluid
Chemiluminescent substances
***Chemotherapy***
Chromosome
Concentration (process)
Cryopreservation
Cryptococcus (fungus)
Cryptococcus (insect)
Culture media
Drugs
Dyes
Ebola virus
Epitopes
Escherichia coli
Fluorescent substances
Fusion, biological
Genetic methods
Hantavirus
Human
Human T-lymphotropic virus 1
Human T-lymphotropic virus 2
Human herpesvirus
Human papillomavirus
Imaging agents
Immobilization, molecular or cellular
Immunity
Influenza virus
Klebsiella
Labels
Lupus erythematosus
Lymph
Lymphoma
Macrophage
Mammary gland
Melanoma
Mus
Neoplasm
Nucleic acid hybridization
Optical imaging devices
Precipitation (chemical)
Prostate gland
Protein sequences
Radiochemical analysis

```
    Rheumatoid arthritis
    Saliva
    Sepsis
    Septicemia
    Staphylococcus
    Streptococcus
    Tear (ocular fluid)
    Test kits
    Testis, neoplasm
    Tetanus
    Urine analysis
    Viremia
      (novel tumor-assocd. marker)
IT  405011-18-9  405011-20-3  405011-22-5  405011-24-7  405011-64-5
     ***405011-66-7***    ***405011-69-0***    405011-71-4  405011-73-6
     ***405011-75-8***    ***405011-77-0***    405011-79-2
    RL: PRP (Properties)
      (unclaimed protein sequence; novel   ***tumor***  -assocd. marker)


=> file reg
COST IN U.S. DOLLARS                        SINCE FILE     TOTAL
                                  ENTRY    SESSION
FULL ESTIMATED COST                           20.97     50.07

FILE 'REGISTRY' ENTERED AT 16:11:12 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   17 MAY 2006  HIGHEST RN 884739-24-6
DICTIONARY FILE UPDATES:  17 MAY 2006  HIGHEST RN 884739-24-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                       *
*************************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s 405011-66-7 or 405011-69-0 or 405011-75-8 or 405011-77-0
          1 405011-66-7
            (405011-66-7/RN)
          1 405011-69-0
            (405011-69-0/RN)
          1 405011-75-8
            (405011-75-8/RN)
          1 405011-77-0
            (405011-77-0/RN)
L10       4 405011-66-7 OR 405011-69-0 OR 405011-75-8 OR 405011-77-0

=> d his
```

```
   (FILE 'HOME' ENTERED AT 16:07:17 ON 18 MAY 2006)

   FILE 'REGISTRY' ENTERED AT 16:07:25 ON 18 MAY 2006
L1      159373 S LPY/SQSP

   FILE 'CAPLUS' ENTERED AT 16:07:44 ON 18 MAY 2006
L2       21611 S L1
L3      708462 S CANCER? OR TUMOR? OR NEOPLAS?
L4        3097 S L2 AND L3
L5         976 S L2 (L) L3
L6       50046 S LIPOSOM?
L7          21 S L5 AND L6
L8      110362 S CHEMOTHER? OR (ANTICANCER OR (ANTI (2W) CANCER))
L9           2 S L8 AND L7

   FILE 'REGISTRY' ENTERED AT 16:11:12 ON 18 MAY 2006
L10          4 S 405011-66-7 OR 405011-69-0 OR 405011-75-8 OR 405011-77-0

=> s l1 and l10
L11          4 L1 AND L10

=> s cn SQL SEQ 1-4
       17719 CN
        4522 CNS
       22240 CN
             (CN OR CNS)
           2 SQL
       17848 SEQ
           1 SEQS
       17849 SEQ
             (SEQ OR SEQS)
    18816078 1
    16897302 4
L12          0 CN SQL SEQ 1-4
             (CN(W)SQL(W)SEQ(W)1(W)4)

=> s l11
L13          4 L1 AND L10

=> d cn SQL SEQ 1-4

L13  ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2006 ACS on STN
CN   21: PN: WO0222851 FIGURE: 41B unclaimed protein (9CI)  (CA INDEX NAME)
SQL  230

SEQ      1 RRMQYNRRFV NVVPTFGKKK GTTFTKIFVG GLPYHTTDAS LRKYFEGFG
                      ===
      51 IEEAVVITDR QTGKSRGYGF VTMADRAAAE RACKDPNPII DGRKANVNLA
     101 YLGAKPWCLQ TGFAIGVQQL HPTLIQRTYG LTPHYIYPPA IVQPSVVIPA
     151 APVPSLSSPY IEYTPASPVY AQYPPATYDQ YPYAASPATA DSFVGYSYPA
     201 AVHQALSAAA PAGTTFVQYQ APQLQPDRMQ
HITS AT:  32-34

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

L13  ANSWER 2 OF 4  REGISTRY  COPYRIGHT 2006 ACS on STN
CN   19: PN: WO0222851 FIGURE: 41A unclaimed protein (9CI)  (CA INDEX NAME)
SQL  229

SEQ      1 SAGFSRPLAA PGVMYGSQKG TTFTKIFVGG LPYHTTDASL RKYFEGFGD
                       ===
      51 EEAVVITDRQ TGKSRGYGFV TMADRAAAER ACKDPNPIID GRKANVNLAY
     101 LGAKPWCLQT GFAIGVQQLH PTLIQRTYGL TPHYIYPPAI VQPSVVIPAA
     151 PVPSLSSPYI EYTPASPVYA QYPPATYDQY PYAASPATAD SFVGYSYPAA
     201 VHQALSAAAP AGTTFVQYQA PQLQPDRMQ
HITS AT:  31-33

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

L13  ANSWER 3 OF 4  REGISTRY  COPYRIGHT 2006 ACS on STN
CN   13: PN: WO0222851 FIGURE: 38 unclaimed protein (9CI)  (CA INDEX NAME)
SQL  197
```

```
SEQ      1 MMFPQSRHSG SSHLPQQLKF TTSDSCDRIK DEFQLLQAQY HSLKLECDI
        51 ASEKSEMQRH YVMYYEMSYG LNIEMHKQAE IVKRLNGICA QVLPYLSQEH
                                   ===
       101 QQQVLGAIER AKQVTAPELN SIIRQQLQAH QLSQLQALAL PLTPLPVGLQ
       151 PPSLPAVSAG TGLLSLSALG SQAHLSKEDK NGHDGDTHQE DDGEKSD
HITS AT:  93-95

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

L13  ANSWER 4 OF 4  REGISTRY  COPYRIGHT 2006 ACS on STN
CN   11: PN: WO0222851 FIGURE: 37 unclaimed protein (9CI)  (CA INDEX NAME)
SQL  196

SEQ      1 MFPQSRHSGS SHLPQQLKFT TSDSCDRIKD EFQLLQAQYH SLKLECDKL
        51 SEKSEMQRHY VMYYEMSYGL NIEMHKQAEI VKRLNGICAQ VLPYLSQEHQ
                                   ===
       101 QQVLGAIERA KQVTAPELNS IIRQQLQAHQ LSQLQALALP LTPLPVGLQP
       151 PSLPAVSAGT GLLSLSALGS QAHLSKEDKN GHDGDTHQED DGEKSD
HITS AT:  92-94

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**


=>

---Logging off of STN---


=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS                SINCE FILE     TOTAL
                                    ENTRY   SESSION
FULL ESTIMATED COST                    51.00    101.07

STN INTERNATIONAL LOGOFF AT 16:13:34 ON 18 MAY 2006
```